摘要
目的探索阿卡波糖与瑞格列奈联合二甲双胍治疗2型糖尿病餐后高血糖的临床效果以及不良反应发生情况。方法选择2型糖尿病100例,选择时间:2017年6月—2018年4月,分别行不同的治疗模式:二甲双胍联合阿卡波糖治疗、瑞格列奈联合二甲双胍治疗,对应组别:对照组、观察组。比较2组血糖数据情况、不良反应发生情况、血脂数据情况、治疗效果。结果观察组空腹血糖:(6.21±1.11)mmol/L、餐后2 h血糖:(8.24±1.25)mmol/L、糖化血红蛋白:(7.15±1.11)%、TC:(5.12±0.36)mmol/L、TC:(2.10±0.36)mmol/L、HDL-C:(2.22±0.36)mmol/L、LDL-C:(2.51±0.42)mmol/L、治疗效果:96.00%,明显优于对照组(t=3.172 4、P=0.002 0;t=4.070 3、P=0.000 1;t=2.421 5、P=0.017 3;t=18.771 2、P=0.000 1;t=8.608 9、P=0.000 1、t=7.602 6、P=0.000 1;t=7.934 0、P=0.000 1;χ~2=8.305 6、t=0.004 0);但在不良反应发生率的比较中,2组数据之间差异无统计学意义(χ~2=0.210 5、P=0.646 4)。结论阿卡波糖与瑞格列奈联合二甲双胍治疗2型糖尿病餐后高血糖的临床效果较佳。
Objective To explore the clinical effects and adverse reactions of acarbose and repaglinide combined with metformin in the treatment of postprandial hyperglycemia in type 2 diabetes.Methods 100 cases of type 2 diabetes were selected.The choice time was from June 2017 to April 2018.Different treatment modes were used:metformin combined with acarbose,repaglinide combined with metformin,corresponding:control group,observation group.Compare the blood glucose data of 2 groups,the occurrence of adverse reactions,blood lipid data,and treatment effects.Results The fasting blood glucose of the observation group:(6.21±1.11)mmol/L,2 h after meal,blood glucose:(8.24±1.25)mmol/L,glycated hemoglobin:(7.15±1.11)%,TC:(5.12±0.36)mmol/L,TC:(2.10±0.36)mmol/L,HDL-C:(2.22±0.36)mmol/L,LDL-C:(2.51±0.42)mmol/L,therapeutic effect:96.00%,significantly better than the control group(t=3.172 4,P=0.002 0;t=4.070 3,P=0.000 1;t=2.421 5,P=0.017 3;t=18.771 2,P=0.000 1;t=8.608 9,P=0.000 1,t=7.602 6,P=0.000 1;t=7.934 0;P=0.000 1;χ^2= 8.305 6,t=0.004 0);however,in the comparison of the incidence of adverse reactions,there was no significant difference between the two groups of data(χ^2=0.210 5,P=0.646 4).Conclusion The clinical effects of acarbose and repaglinide combined with metformin in the treatment of postprandial hyperglycemia in type 2 diabetes are better.
作者
齐桂花
QI Gui-hua(Pharmacy Department,Linyi County People's Hospital,Dezhou,Shandong Province,251500 China)
出处
《系统医学》
2019年第2期123-125,共3页
Systems Medicine
